Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Irinotecan

Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1

DRUG

Leukovorin

Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3

DRUG

Oxaliplatin

Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV

DRUG

5-FLUOROURACIL

5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3

DRUG

Cetuximab

Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy

Trial Locations (1)

Unknown

University Hospital of Crete, Heraklion

All Listed Sponsors
lead

University Hospital of Crete

OTHER

NCT00689624 - Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | Biotech Hunter | Biotech Hunter